Latest

Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆

Trackers› Clinical trials› Hamburg

Clinical trial register · Germany

Clinical Trials in Hamburg, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC

5051

Studies in scope

all four open statuses

2882

Recruiting now

open to new participants

988

Lead sponsors

across recruiting studies

Top sites

Hamburg 25 Berlin 24 Munich 22 Ulm 21 Freiburg im Breisgau 20

Trials with a site in Hamburg

Status

Study

Lead sponsor

Phase

Enrol

Sites in Germany

Start

Recruiting

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

NCT07525206Colorectal Cancer

DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab

AbbVie

Phase 3

990

Reutlingen, Munich, Dresden, Berlin, Hamburg

2026-05-22

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Heidelberg, Würzburg, Marburg, Cologne, Jena, Hamburg

2025-12-10

Recruiting

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

NCT07039110Plaque Psoriasis

AbbVie

Observational

700

Friedrichshafen, Kulmbach, Munich, Potsdam, Dortmund, Mainz, Mölln, Hamburg

2025-09-09

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

NCT06953960Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone

AbbVie

Phase 1/2

325

Heidelberg, Munich, Würzburg, Hamburg

2025-07-23

Recruiting

A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis

NCT06972446Rheumatoid Arthritis

DrugsABBV-8736·ABBV-701·Lutikizumab·Adalimumab

AbbVie

Phase 2

180

Wetzlar, Bonn, Cologne, Hamburg

2025-06-20

Active, closed

A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT06291220Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsABBV-453·Obinutuzumab

AbbVie

Phase 1

4

Ulm, Halle, Kiel, Berlin, Hamburg

2025-01-27

Active, closed

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

NCT06628310Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

DrugsBudigalimab·Telisotuzumab Adizutecan·Fluorouracil·Leucovorin

AbbVie

Phase 2

185

Freiburg im Breisgau, Munich, Frankfurt am Main, Leipzig, Hamburg

2024-12-13

Recruiting

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744Juvenile Psoriatic Arthritis

DrugsSkyrizi·Risankizumab·Adalimumab

AbbVie

Phase 3

40

Sankt Augustin, Berlin, Hamburg

2024-07-08

Active, closed

Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06223516Multiple Myeloma

AbbVie

Phase 1

60

Frankfurt am Main, Cologne, Hamburg

2024-06-17

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Freiburg im Breisgau, Karlsruhe, Chemnitz, Berlin, Frankfurt am Main, Hamburg

2024-05-19

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

NCT06257875Ulcerative Colitis

DrugsLutikizumab·Humira·Adalimumab

AbbVie

Phase 2

156

Ulm, Munich, Ludwigshafen am Rhein, Leipzig, Kiel, Hamburg

2024-03-23

Active, closed

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

NCT06107413Unresectable Metastatic Colorectal Cancer

DrugsFolinic acid·Telisotuzumab Adizutecan·Fluorouracil·Irinotecan

AbbVie

Phase 2

280

Mannheim, Tübingen, Ulm, Dresden, Berlin, Hamburg

2023-11-12

Recruiting

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

NCT05609630Juvenile Idiopathic Arthritis

DrugsUpadacitinib·Tocilizumab

AbbVie

Phase 3

90

Freiburg im Breisgau, Sankt Augustin, Sendenhorst, Berlin, Hamburg

2023-10-02

Active, closed

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

NCT05753501Hematologic Cancer

AbbVie

Phase 1

135

Ulm, Würzburg, Rostock, Homburg, Berlin, Hamburg

2023-06-09

Active, closed

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05259839Relapsed/Refractory Multiple Myeloma

DrugsEtentamig·Pomalidomide·Daratumumab·Lenalidomide

AbbVie

Phase 1

283

Tübingen, Regensburg, Würzburg, Essen, Hamburg

2022-10-20

Active, closed

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636AMD, nAMD, Wet Age-related Macular Degeneration, wAMD

DrugsEylea·Aflibercept

AbbVie

Phase 3

735

Freiburg im Breisgau, Ulm, Bonn, Münster, Ludwigshafen am Rhein, Hamburg, Püttlingen

2022-01-13

Active, closed

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

NCT05139602Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 2

210

Erlangen, Berlin, Bochum, Dessau, Hamburg

2021-12-28

Active, closed

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

NCT04468984Myelofibrosis (MF)

DrugsNavitoclax·Ruxolitinib

AbbVie

Phase 3

330

Mannheim, Mutlangen, Augsburg, Rostock, Bochum, Chemnitz, Dresden, Hamburg

2020-08-31

Active, closed

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Upadacitinib in Pediatric Subjects With Polyarticular Course Juvenile Idiopathic Arthritis

NCT03725007Juvenile Idiopathic Arthritis (JIA)

DrugUpadacitinib

AbbVie

Phase 1

124

Sankt Augustin, Sendenhorst, Bad Bramstedt, Berlin, Hamburg

2019-06-24

Active, closed

A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

NCT03933735Multiple Myeloma

AbbVie

Phase 1/2

220

Cologne, Münster, Dresden, Hamburg

2019-06-24

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

Herne, Buch, Frankfurt, Hamburg

2019-03-25

Active, closed

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

NCT03539744Multiple Myeloma

DrugsPomalidomide·Venetoclax·Dexamethasone

AbbVie

Phase 3

265

Stuttgart, Tübingen, Würzburg, Chemnitz, Kiel, Jena, Berlin, Hamburg

2018-10-22

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

Heidelberg, Frankfurt am Main, Münster, Selters, Kiel, Bonn, Hamburg, Hanover

2018-08-09

Active, closed

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

NCT02993523Acute Myeloid Leukemia (AML)

DrugsAzacitidine·Venetoclax

AbbVie

Phase 3

443

Ulm, Frankfurt am Main, Münster, Halle, Hamburg, Hanover

2017-02-02

Active, closed

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

NCT02629159Rheumatoid Arthritis

DrugsHumira·Adalimumab·Upadacitinib

AbbVie

Phase 3

1,629

Cologne, Herne, Rendsburg, Chemnitz, Hamburg, Munich

2015-12-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-germany/city/hamburg

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies with a site in Hamburg that also match the filters currently applied.

How many clinical trials are recruiting in Hamburg?

7 of the 25 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 18 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hamburg), 25 studies
Phase	Studies	Recruiting	Share
Phase 3	11	3	44%
Phase 1	5	0	20%
Phase 2	5	1	20%
Phase 1/2	2	1	8%
Observational	1	1	4%
Phase 2/3	1	1	4%

Most active sponsors

Lead sponsors with the most studies (Hamburg)
Lead sponsor	Studies	Recruiting
AbbVie	25	7

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.